目的：临床应用表明７６４复方对肝癌、胰腺癌等有治疗作用。为了证实该复方水溶性提取物的抗癌作用，并探索其机理，进行了该实验研究，以期为临床研究和应用提供科学依据。方法：体内抑癌实验共进行３次。每次分３组，即阳性对照组（５－Ｆｕ），阴性对照组（ＤＨ２Ｏ），实验组（７６４复方）。结束时，剥离肿瘤，称瘤重和体重，计算抑瘤率，并用ｔ检验作统计学处理；第３次实验中，各组动物体内注射Ｂｒｄｕ，免疫组化检测肿瘤组织中Ｂｒｄｕ、ＰＣＮＡ标记细胞，光镜观察，计数Ｂｒｄｕ、ＰＣＮＡ标记细胞，用卡方检验作统计学处理。结果：３次实验结果，７６４复方的抑瘤率分别为４７．２％，４５．６％和４６．８％，与对照组比有显著性差异（Ｐ＜０．０１）；Ｂｒｄｕ标记细胞为５６．１±７．９，ＰＣＮＡ阳性细胞为４４１．１±２８．７，均低于对照组（８４．４±２４．３，６９４．０±１１７．１）有显著性差异（Ｐ＜０．０１）。结论：７６４复方有抗肝癌作用，其机理可能与抑制ＤＮＡ合成、ＰＣＮＡ表达和ＤＮＡ多聚酶δ活性有关 Objective: Clinical application shows that 764 compound has therapeutic effects on liver cancer, pancreatic cancer and so on. In order to prove the anti-cancer effect of the compound water-soluble extract and explore its mechanism, this experimental study was conducted in order to provide scientific basis for clinical research and application. Methods: In vivo tumor suppressor experiments were performed 3 times. Each group was divided into 3 groups: positive control group (5-Fu), negative control group (DH2O), and experimental group (764 compound). At the end of the experiment, the tumors were detached and the tumor weight and body weight were weighed. The rate of tumor inhibition was calculated and statistically treated with the t-test. In the third experiment, Brdu was injected into the animals in each group. Brdu and PCNA-labeled cells were detected by immunohistochemistry. , Observe by light microscope, count Brdu, PCNA-labeled cells and use Chi-square test for statistical analysis. Results: The results of 3 experiments showed that the inhibitory rate of 764 Compound was 47.2%, 45.6% and 46.8%, respectively, and there was a significant difference compared with the control group (P<0.01); Brdu labeled cells were 56.1±7.9, PCNA-positive cells were 441.1±28.7, which were significantly lower than the control group (84.4±24.3, 694.0±117.1) (P<0 .01). Conclusion: Compound 764 has anti-hepatocarcinoma effects and its mechanism may be related to inhibition of DNA synthesis, PCNA expression and DNA polymerase δ activity.